Hyperliquid Strategies Inc. (NasdaqCM: PURR)
Health Care · Biotechnology · US
$11.11
-1.68% today · +184.9% 1Y
Hyperliquid Strategies Inc. (NasdaqCM: PURR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.20B and employs 9 people.
Over the last twelve months the share price has gained 184.9%, trading between 3.01 and 14.76.
Tweenvest scores Hyperliquid Strategies Inc. across four factors: quality 78/100, value 32/100. Its strongest factor is quality.
PURR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.20B
- Revenue (TTM)
- $9.46M
- P/E
- 3.46
- EPS
- 3.21
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $14.76
- 52-week low
- $3.01
- Avg volume (3M)
- —
- Shares outstanding
- 197.84M
- Employees
- 9
- Next earnings
- —
About Hyperliquid Strategies Inc.
Hyperliquid Strategies, Inc. operates as both a holding and an active management firm, specializing in the oversight of crypto assets. The company functions primarily as a digital asset treasury, with a dedicated focus on the Hyperliquid ecosystem. Established on July 2, 2025, its corporate headquarters are situated in New York, NY.
- ISIN
- US44916Y1064
- Listed since
- Dec 2, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CanSino Biologics Inc.SEHK: 6185 | $2.27B | HK$35.02 | +1.10% |
| Shenzhen Kangtai Biological Products Co., Ltd.SZSE: 300601 | $2.24B | CN¥13.44 | -1.03% |
| Immunome, Inc.NasdaqCM: IMNM | $2.22B | $19.31 | -1.23% |
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.22B | $16.64 | -0.06% |
| BioCryst Pharmaceuticals, Inc.NasdaqGS: BCRX | $2.18B | $8.36 | -2.28% |
| Vera Therapeutics, Inc.NasdaqGM: VERA | $2.15B | $28.17 | -5.72% |
| SK bioscience Co.,Ltd.KOSE: A302440 | $2.13B | ₩36,750.00 | +0.68% |
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | $2.12B | CN¥8.53 | +1.79% |
Figures last refreshed Oct 11, 2026.